KR101633957B1 - 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 - Google Patents

피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 Download PDF

Info

Publication number
KR101633957B1
KR101633957B1 KR1020120093936A KR20120093936A KR101633957B1 KR 101633957 B1 KR101633957 B1 KR 101633957B1 KR 1020120093936 A KR1020120093936 A KR 1020120093936A KR 20120093936 A KR20120093936 A KR 20120093936A KR 101633957 B1 KR101633957 B1 KR 101633957B1
Authority
KR
South Korea
Prior art keywords
pyrazol
pyridin
compound
propyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020120093936A
Other languages
English (en)
Korean (ko)
Other versions
KR20140027833A (ko
Inventor
배윤수
하헌주
이기인
송경희
Original Assignee
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020120093936A priority Critical patent/KR101633957B1/ko
Application filed by 이화여자대학교 산학협력단 filed Critical 이화여자대학교 산학협력단
Priority to CN201380056244.5A priority patent/CN104755077B/zh
Priority to ES13834243T priority patent/ES2734264T3/es
Priority to EP13834243.1A priority patent/EP2889032B1/en
Priority to US14/424,771 priority patent/US10047067B2/en
Priority to PCT/KR2013/006985 priority patent/WO2014035070A1/ko
Priority to TR2019/09923T priority patent/TR201909923T4/tr
Priority to JP2015529664A priority patent/JP5974180B2/ja
Priority to PL13834243T priority patent/PL2889032T3/pl
Publication of KR20140027833A publication Critical patent/KR20140027833A/ko
Application granted granted Critical
Publication of KR101633957B1 publication Critical patent/KR101633957B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020120093936A 2012-08-27 2012-08-27 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 Active KR101633957B1 (ko)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020120093936A KR101633957B1 (ko) 2012-08-27 2012-08-27 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
ES13834243T ES2734264T3 (es) 2012-08-27 2013-08-02 Composición para prevenir o tratar enfermedad renal que comprende derivado de pirazol
EP13834243.1A EP2889032B1 (en) 2012-08-27 2013-08-02 Composition for preventing or treating kidney disease comprising pyrazole derivative
US14/424,771 US10047067B2 (en) 2012-08-27 2013-08-02 Composition for treating kidney disease comprising pyrazole derivative
CN201380056244.5A CN104755077B (zh) 2012-08-27 2013-08-02 用于预防或治疗肾脏疾病的包含吡唑衍生物的组合物
PCT/KR2013/006985 WO2014035070A1 (ko) 2012-08-27 2013-08-02 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
TR2019/09923T TR201909923T4 (tr) 2012-08-27 2013-08-02 Böbrek hastalığının önlenmesi ya da tedavisi için pirazol türevini ihtiva eden kompozisyon.
JP2015529664A JP5974180B2 (ja) 2012-08-27 2013-08-02 ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物
PL13834243T PL2889032T3 (pl) 2012-08-27 2013-08-02 Kompozycja zawierająca pochodną pirazolu do zapobiegania lub leczenia choroby nerek

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120093936A KR101633957B1 (ko) 2012-08-27 2012-08-27 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
KR20140027833A KR20140027833A (ko) 2014-03-07
KR101633957B1 true KR101633957B1 (ko) 2016-06-27

Family

ID=50183832

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120093936A Active KR101633957B1 (ko) 2012-08-27 2012-08-27 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물

Country Status (9)

Country Link
US (1) US10047067B2 (https=)
EP (1) EP2889032B1 (https=)
JP (1) JP5974180B2 (https=)
KR (1) KR101633957B1 (https=)
CN (1) CN104755077B (https=)
ES (1) ES2734264T3 (https=)
PL (1) PL2889032T3 (https=)
TR (1) TR201909923T4 (https=)
WO (1) WO2014035070A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101840702B1 (ko) 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
WO2018194416A1 (ko) 2017-04-20 2018-10-25 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
WO2021101344A1 (ko) 2019-11-21 2021-05-27 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물
KR102277665B1 (ko) 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
KR20220133041A (ko) 2021-03-24 2022-10-04 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101826208B1 (ko) 2016-02-05 2018-02-06 경북대학교 산학협력단 뉴로펩타이드 y를 유효성분으로 포함하는, 신장질환의 예방 또는 치료용 약학적 조성물
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
US20230201179A1 (en) * 2020-04-08 2023-06-29 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
KR102386097B1 (ko) * 2020-04-13 2022-04-14 압타바이오 주식회사 피라졸 유도체의 폐섬유증 치료제
CN115427039B (zh) * 2020-04-13 2025-04-04 阿普塔生物治疗公司 包含吡唑衍生物的肺纤维化药物
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
CN119504599B (zh) * 2024-11-18 2025-09-26 安徽医科大学 一种用于治疗肾脏纤维化的吡唑类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023488A1 (de) 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
WO1993007138A1 (fr) 1991-10-08 1993-04-15 Nippon Soda Co., Ltd. Derive de pyrazole et bactericide utilisable en agriculture/horticulture contenant ce derive
JP2003098120A (ja) 2001-09-26 2003-04-03 Tokyo Weld Co Ltd 外観検査装置
JP4189850B2 (ja) 2002-05-20 2008-12-03 味の素株式会社 線維化病変組織修復剤
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
WO2006129587A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体を含有する医薬組成物
CN101511818B (zh) * 2006-09-01 2013-05-08 大塚农业科技株式会社 N-吡啶基哌啶化合物、其制备方法及有害生物防治剂
KR100942382B1 (ko) 2008-03-25 2010-02-12 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물
KR101280198B1 (ko) 2009-09-02 2013-06-28 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
WO2011028043A2 (ko) * 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018194416A1 (ko) 2017-04-20 2018-10-25 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
US11174240B2 (en) 2017-04-20 2021-11-16 Aptabio Therapeutics Inc. Crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride
KR101840702B1 (ko) 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
WO2019088444A1 (en) 2017-11-01 2019-05-09 Aptabio Therapeutics Inc. Therapeutic agent for liver diseases
WO2021101344A1 (ko) 2019-11-21 2021-05-27 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물
KR20210062586A (ko) 2019-11-21 2021-05-31 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물
KR102277665B1 (ko) 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
WO2021157818A1 (ko) * 2020-02-05 2021-08-12 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
KR20220133041A (ko) 2021-03-24 2022-10-04 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물

Also Published As

Publication number Publication date
JP2015531774A (ja) 2015-11-05
US20150218125A1 (en) 2015-08-06
JP5974180B2 (ja) 2016-08-23
PL2889032T3 (pl) 2019-09-30
US10047067B2 (en) 2018-08-14
EP2889032A1 (en) 2015-07-01
TR201909923T4 (tr) 2019-07-22
EP2889032A4 (en) 2016-03-09
ES2734264T3 (es) 2019-12-05
EP2889032B1 (en) 2019-05-08
CN104755077A (zh) 2015-07-01
WO2014035070A1 (ko) 2014-03-06
KR20140027833A (ko) 2014-03-07
CN104755077B (zh) 2018-05-15

Similar Documents

Publication Publication Date Title
KR101633957B1 (ko) 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
RU2293733C2 (ru) Новые 1,2,4-триазольные соединения, способы их получения и содержащие их лекарственные средства
US8637674B2 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
CA2862030C (en) Apoptosis signal-regulating kinase inhibitor
KR101840702B1 (ko) 간질환 치료제
WO2002051442A1 (en) Concomitant drugs
KR101630432B1 (ko) 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
KR101302315B1 (ko) 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
JP2024153885A (ja) 新規なピラゾール誘導体
KR20110133040A (ko) 프로스타글란딘 ｄ 합성 효소를 저해하는 피페라진 화합물
JP2013501812A (ja) 炎症またはエネルギー代謝／産生関連疾患の治療または予防のためのＰＰＡＲδリガンドの使用
MX2013009904A (es) Derivados de pirazol, metodo de preparacion de los mismos, y composicion que contiene los mismos para prevenir y tratar la osteoporosis.
KR101280720B1 (ko) 1，2，3，4，6―펜타―오―갈로일―베타―디―글루코오스및 이마티니브를 유효성분으로 포함하는 만성 골수성 백혈병 치료용 조성물
JP4662979B2 (ja) 新規なβ−アゴニスト、その製造方法及びその薬物としての使用
AU2014244855B2 (en) Pyrazole derivative
KR101683362B1 (ko) 소양증 개선 활성을 갖는 벤즈옥사졸 유도체
RU2846904C1 (ru) Новое производное пиразола
RU2846904C9 (ru) Новое производное пиразола
CN115974719B (zh) 化合物、包括所述化合物的药物组合物及其用途
AU2015201188B2 (en) Apoptosis signal-regulating kinase inhibitor

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

FPAY Annual fee payment

Payment date: 20190325

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20200422

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20210428

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20220406

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11